Intrinsic Value of S&P & Nasdaq Contact Us

LivaNova PLC LIVN NASDAQ

NASDAQ Global Select • Healthcare • Medical - Devices • GB • USD

SharesGrow Score
56/100
3/7 Pass
SharesGrow Intrinsic Value
$136.08
+109.4%
Analyst Price Target
$75.88
+16.8%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

LivaNova PLC (LIVN) has a negative trailing P/E of -14.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 15.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -6.99%, forward earnings yield 6.48%. PEG 1.39.

Criteria proven by this page:

  • VALUE (71/100, Pass) — analyst target implies upside (+16.8%).
  • Forward P/E 15.4 — analysts expect a return to profitability with estimated EPS of $4.21 for FY2026.
  • PEG Ratio 1.39 — between 1.0–2.0 indicates moderate valuation relative to growth.
  • Trailing Earnings Yield -6.99% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 6.48% as earnings recover.
  • Analyst consensus target $75.88 (+16.8% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 56/100 with 3/7 criteria passed.

SharesGrow 7-Criteria Score
56/100
SG Score
View full scorecard →
VALUE
71/100
Price-to-Earnings & upside
Proven by this page
FUTURE
79/100
Analyst consensus
→ Forecast
~
PAST
50/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
MOAT
70/100
→ Income
~
GROWTH
48/100
→ Income
INCOME
10/100
→ Income

Valuation Snapshot — LIVN

Valuation Multiples
P/E (TTM)-14.3
Forward P/E15.4
PEG Ratio1.39
Forward PEG1.39
P/B Ratio2.89
P/S Ratio2.51
EV/EBITDA-27.5
Per Share Data
EPS (TTM)$-4.45
Forward EPS (Est.)$4.21
Book Value / Share$22.02
Revenue / Share$25.47
FCF / Share$3.18
Yields & Fair Value
Earnings Yield-6.99%
Forward Earnings Yield6.48%
Dividend Yield0.00%
SharesGrow IV$136.08 (+109.4%)
Analyst Target$75.88 (+16.8%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2016 -35.0 0.22 1.29 1.81 -
2017 -153.5 2.57 2.12 3.81 -
2018 -23.4 -0.04 2.95 4.01 -
2019 -23.1 1.31 2.64 3.36 -
2020 -9.2 -0.08 2.90 3.44 -
2021 -32.6 0.53 3.42 4.28 -
2022 -34.5 0.86 2.46 2.91 -
2023 158.9 -1.32 2.18 2.42 -
2024 39.7 0.16 1.90 2.00 -
2025 -13.8 0.03 2.79 2.42 -

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $-1.28 $1.21B $-62.8M -5.2%
2017 $-0.52 $1.01B $-25.1M -2.5%
2018 $-3.91 $1.11B $-189.4M -17.1%
2019 $-3.22 $1.08B $-155.5M -14.3%
2020 $-7.06 $934.2M $-343.3M -36.7%
2021 $-2.68 $1.04B $-135.7M -13.1%
2022 $-1.61 $1.02B $-86.2M -8.4%
2023 $0.32 $1.15B $17.55M 1.5%
2024 $1.16 $1.25B $63.23M 5%
2025 $-4.45 $1.39B $-242.5M -17.5%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $4.21 $4.19 – $4.22 $1.49B $1.47B – $1.52B 6
2027 $4.58 $4.52 – $4.61 $1.6B $1.54B – $1.64B 6
2028 $5.05 $4.60 – $5.50 $1.74B $1.72B – $1.76B 2
2029 $5.81 $5.57 – $5.92 $1.75B $1.69B – $1.78B 1
2030 $6.41 $6.14 – $6.53 $1.86B $1.8B – $1.89B 1
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message